EU drug regulator EMA expects Johnson & Johnson (JNJ) to file for approval of its COVID-19 vaccine in the next few days - Reuters
Tweet
Share
E-mail
Get Alerts JNJ Hot Sheet
Price: $160.39 +0.29%
Overall Analyst Rating:
BUY (
Up)
Dividend Yield: 2.5%
EPS Growth %: -1.1%
Overall Analyst Rating:
BUY (
Up)Dividend Yield: 2.5%
EPS Growth %: -1.1%
Trade Now!
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
EU drug regulator EMA expects Johnson & Johnson (NYSE: JNJ) to file for approval of its COVID-19 vaccine in the next few days - Reuters
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CDC Panel Tentatively Set to Met Late Next Week on J&J (JNJ) Shot - Bloomberg
- Coinbase (COIN) Adds to Gains
- Fauci says he believes J&J vaccine will 'get back on track soon'
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
